Pre-made Nemolizumab benchmark antibody ( Whole mAb, anti-IL31RA/IL31R therapeutic antibody, Anti-CRL/CRL3/GLM-R/GLMR/GPL/IL-31RA/PLCA2/PRO21384/hGLM-R/zcytoR17 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Nemolizumab biosimilar, Whole mAb, Anti-IL31RA/IL31R Antibody: Anti-CRL/CRL3/GLM-R/GLMR/GPL/IL-31RA/PLCA2/PRO21384/hGLM-R/zcytoR17 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Nemolizumab is an experimental drug for the treatment of itching in people with atopic dermatitis. It is a monoclonal antibody that blocks the interleukin-31 receptor A. Results of a Phase II clinical trial were published in March 2017.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-372-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Nemolizumab biosimilar, Whole mAb, Anti-IL31RA/IL31R Antibody: Anti-CRL/CRL3/GLM-R/GLMR/GPL/IL-31RA/PLCA2/PRO21384/hGLM-R/zcytoR17 therapeutic antibody
INN Name	Nemolizumab
Target	IL31R
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2014
Year Recommended	2015
Companies	Chugai Pharmaceutical;Galderma;Maruho
Conditions Approved	na
Conditions Active	Atopic dermatitis;Prurigo nodularis;Pruritus
Conditions Discontinued	na
Development Tech	na